Is Nintedanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Article
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
[powerpress]